Table 1.
Clinical characteristics of PCaP AA research subjects in data analysis
| NC | LA | |
|---|---|---|
| No. of research subjects | 447 | 543 |
| Age at diagnosis | ||
| Median | 60 | 63 |
| Range | 41-79 | 43-79 |
| Mean African ancestry (%) | 82.0 | 79.3 |
| Median PSA ng/ml | 6 | 6 |
| PSA levels N (%) | ||
| < 4 ng/ml | 40 (8.9) | 65 (12) |
| 4-10 ng/ml | 276 (61.7) | 305 (54.2) |
| 10-20 ng/ml | 74 (16.7) | 83 15.3) |
| > 20 ng/ml | 52 (11.6) | 56 (10.3) |
| Unknown | 5(1.1) | 34 (6.2) |
| Gleason Score, N (%) | ||
| ≤6 | 237 (53.0) | 309 (56.9) |
| 7 | 155 (34.7) | 157 (28.9) |
| 8-10 | 55 (12.3) | 76 (14.0) |
| Unknown | 0 (0) | 1 (0.2) |
| Pathologic stage, N (%) | ||
| T1 | 274 (61.3) | 266 (49.0) |
| T2 | 162 (36.3) | 246 (45.3) |
| T3-T4 | 9 (2.0) | 8 (1.5) |
| Unknown | 2 (0.4) | 23 (4.2) |
| Aggressiveness, N (%) | ||
| Low | 203 (45.4) | 244 (45.0) |
| Intermediate | 157 (35.1) | 159 (29.3) |
| High | 87 (19.5) | 110 (20.2) |
| Unknown | 0 (0) | 30 (5.5) |